Target- |
Mechanism- |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 2001 |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.United States |
First Approval Date31 May 1983 |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.China |
First Approval Date01 Jan 1982 |
/ Active, not recruitingNot Applicable [Translation] Bioequivalence study of mesalazine enema solution in humans under fasting conditions
主要目的:考察健康试验参与者在空腹条件下,单次使用由陕西九州制药有限责任公司提供的美沙拉秦灌肠液(受试制剂,规格:60g:4g)与相同条件下单次使用由Dr. Falk Pharma GmbH持证的美沙拉秦灌肠液(参比制剂,商品名:Salofalk®,规格:60g:4g)的药动学特征,评价两制剂的生物等效性,为该受试制剂注册申请提供依据。
次要目的:观察单次使用受试制剂或参比制剂在健康试验参与者中的安全性。
[Translation] Primary Objective: To investigate the pharmacokinetic characteristics of a single administration of mesalazine enema solution (test formulation, 60g:4g) provided by Shaanxi Jiuzhou Pharmaceutical Co., Ltd., and a single administration of mesalazine enema solution (reference formulation, Salofalk®, 60g:4g) certified by Dr. Falk Pharma GmbH, under the same fasting conditions, in healthy trial participants. The bioequivalence of the two formulations will be evaluated, providing a basis for the registration application of the test formulation.
Secondary Objective: To observe the safety of a single administration of either the test formulation or the reference formulation in healthy trial participants.
/ CompletedNot Applicable [Translation] Preliminary human bioequivalence study of mesalazine enema solution under fasting conditions
考察健康试验参与者在空腹条件下单次使用由陕西九州制药有限责任公司提供的美沙拉秦灌肠液(受试制剂,规格:60g:4g)或由Dr. Falk Pharma GmbH持证的美沙拉秦灌肠液(参比制剂,商品名:Salofalk®,规格:60g:4g)的药动学特征,比较两制剂间药动学参数AUC和Cmax的差异,初步评估两制剂的生物等效性,为制剂工艺是否需要进一步优化提供参考。
[Translation] This study investigated the pharmacokinetic characteristics of a single fasting administration of mesalazine enema solution (test formulation, 60g:4g) provided by Shaanxi Jiuzhou Pharmaceutical Co., Ltd., or mesalazine enema solution (reference formulation, trade name: Salofalk®, 60g:4g) certified by Dr. Falk Pharma GmbH. Differences in the pharmacokinetic parameters AUC and Cmax between the two formulations were compared to preliminarily assess their bioequivalence and provide a reference for determining whether further optimization of the formulation process is needed.
/ CompletedNot Applicable [Translation] Preliminary human bioequivalence study of mesalazine enema solution under fasting conditions
考察健康研究参与者在空腹条件下单次使用由陕西九州制药有限责任公司提供的美沙拉秦灌肠液(受试制剂,规格:60g:4g)或由Dr. Falk Pharma GmbH持证的美沙拉秦灌肠液(参比制剂,商品名:Salofalk®,规格:60g:4g)的药动学特征,比较两制剂间药动学参数AUC和Cmax的差异,初步评估两制剂的生物等效性,为制剂工艺是否需要进一步优化提供参考。
[Translation] This study investigated the pharmacokinetic characteristics of a single fasting administration of mesalazine enema solution (test formulation, 60g:4g) provided by Shaanxi Jiuzhou Pharmaceutical Co., Ltd., or mesalazine enema solution (reference formulation, trade name: Salofalk®, 60g:4g) certified by Dr. Falk Pharma GmbH. Differences in the pharmacokinetic parameters AUC and Cmax between the two formulations were compared to preliminarily assess their bioequivalence and provide a reference for determining whether further optimization of the formulation process is needed.
100 Clinical Results associated with Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.
100 Deals associated with Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Huadong Medicine (xi'an) Bodyguard Pharmaceutical Co., Ltd.